Healthcare Revenue Cycle and Finance







Biosimilars, Saving Costs on Specialty Drugs

By Tom Dorsett – As of April 2023, the FDA has approved the use of 40 “biosimilars”, which are a less expensive version of an advanced “biologic” medication. The rise of biosimilars is a major source of excitement as a way to control rising drug costs. But is the fervor warranted?